



Consolidated Financial Results **for the Six Months Ended June 30, 2025** **[IFRS]**

August 6, 2025

Company name: Nissha Co., Ltd.
 Stock exchange listing: Tokyo Stock Exchange
 Code number: 7915
 URL: <https://www.nissha.com/english>
 Representative: Junya Suzuki, Chairman of the Board and Group CEO
 Contact: Daisuke Inoue, Director of the Board, Senior Executive Vice President, Interim CFO
 Phone: +81-75-811-8111
 Scheduled date of filing semi-annual securities report: August 7, 2025
 Scheduled date of commencing dividend payments: September 1, 2025
 Availability of supplementary briefing material on financial results: Available
 Schedule of financial results briefing session: Scheduled (for institutional investors)

(Amounts of less than one million yen are rounded down)

1. Consolidated Financial Results for the Six Months Ended June 30, 2025 (January 1, 2025 to June 30, 2025)

(1) Consolidated Operating Results (cumulative) (% indicates changes from the previous corresponding period)

	Net sales		Operating profit		Profit before tax		Profit		Profit attributable to owners of parent		Total comprehensive income	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Six months ended June 30, 2025	97,049	(2.6)	2,693	(36.9)	1,218	(79.7)	361	(91.6)	129	(97.0)	(4,018)	—
Six months ended June 30, 2024	99,661	20.1	4,266	—	6,007	452.4	4,320	449.1	4,258	431.6	15,078	95.1

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
Six months ended June 30, 2025	2.72	—
Six months ended June 30, 2024	88.04	—

- (Notes) 1. The Company finalized the provisional accounting treatment pertaining to business combination in the six months ended June 30, 2025, and reflected the details of the finalization of the provisional accounting treatment on figures related to the six months ended June 30, 2024.
2. The percentage change in operating profit from the previous corresponding first half is written as "-" because it is 1,000% or more.

(2) Consolidated Financial Position

	Total assets	Total equity	Equity attributable to owners of parent	Ratio of equity attributable to owners of parent to total assets
	Million yen	Million yen	Million yen	%
As of June 30, 2025	239,655	111,055	108,829	45.4
As of December 31, 2024	251,946	115,212	114,028	45.3

(Note) The Company finalized the provisional accounting treatment pertaining to business combination in the six months ended June 30, 2025, and reflected the details of the finalization of the provisional accounting treatment on figures related to the fiscal year ended December 31, 2024.

2. Dividends

	Annual dividends				
	1st quarter-end	2nd quarter-end	3rd quarter-end	Year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended December 31, 2024	—	25.00	—	25.00	50.00
Fiscal year ending December 31, 2025	—	25.00			
Fiscal year ending December 31, 2025 (Forecast)			—	25.00	50.00

(Note) Revision of cash dividend forecast most recently announced: No

3. Consolidated Financial Results Forecast for the Fiscal Year Ending December 31, 2025 (January 1, 2025 to December 31, 2025)

(% indicates changes from the previous corresponding period)

(% indicates changes from the previous corresponding period)

	Net sales		Operating profit		Profit before tax		Profit attributable to owners of parent		Basic earnings per share
Full year	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
	190,800	(2.5)	6,600	20.3	4,600	(26.1)	2,500	(35.4)	52.80

(Notes) 1. Revision of consolidated financial results forecast most recently announced: Yes

2. Changes from the previous corresponding period are calculated based on figures after retrospective adjustments, reflecting the finalization of the provisional accounting treatment related to the business combination conducted in the six months ended June 30, 2025.

Notes:

(1) Significant changes in the scope of consolidation during the period under review: No

New: – (), Exclusion: – ()

(2) Changes in accounting policies and changes in accounting estimates

1) Changes in accounting policies required by IFRS: No

2) Any changes other than 1) above: No

3) Changes in accounting estimates: No

(3) Total number of issued shares (common stock)

1) Total number of issued shares at the end of the period (including treasury shares):

As of June 30, 2025	50,855,638 shares
As of December 31, 2024	50,855,638 shares

2) Total number of treasury shares at the end of the period:

As of June 30, 2025	3,510,024 shares
As of December 31, 2024	3,112,739 shares

3) Average number of shares outstanding during the period (cumulative total):

Six months ended June 30, 2025	47,465,043 shares
Six months ended June 30, 2024	48,368,661 shares

* Semi-annual financial results reports are exempt from review conducted by certified public accountants or an audit firm.

* Explanation of the proper use of financial results forecast and other notes

The performance forecasts and other forward-looking statements contained in this report are based on information available to the Company on the date of this report's release and certain premises that the Company deems to be reasonable. Therefore, the Company has not prepared these descriptions with intent to commit to realize them. Actual results, etc., may differ significantly from the forecasts, however, as a consequence of various factors in the future. For details on the premises of the performance forecasts of the Company and the points to note when using the performance forecasts, please see "1. Qualitative Information on Consolidated Financial Results for the Period under Review, (3) Explanation of consolidated operating results forecast and other forecast information" on page 5 of the appendix.

We are scheduled to hold a briefing session for institutional investors on Wednesday, August 6, 2025. Reference materials to be distributed at the briefing session are scheduled to be posted on our website on that day, as well.

Contents of Appendix

1. Qualitative Information on Consolidated Financial Results for the Period under Review	2
(1) Explanation of operating results	2
(2) Explanation of financial position	4
(3) Explanation of consolidated operating results forecast and other forecast information	5
2. Condensed Consolidated Financial Statements and Principal Notes	6
(1) Condensed consolidated statements of financial position.....	6
(2) Condensed consolidated statements of profit or loss and comprehensive income.....	8
Condensed consolidated statements of profit or loss.....	8
Condensed consolidated statements of comprehensive income	9
(3) Condensed consolidated statements of changes in equity.....	10
(4) Condensed consolidated statements of cash flows	11
(5) Notes to condensed consolidated financial statements	13
(Notes to going concern assumptions).....	13
(Segment information).....	13

1. Qualitative Information on Consolidated Financial Results for the Period under Review

The provisional accounting treatment for the business combination with Isometric Intermediate LLC and its group companies, conducted on March 1, 2024, was finalized during the six months ended June 30, 2025. Accordingly, revised figures based on the finalization of the provisional accounting treatment have been used for the comparative analysis with figures both for the six months ended June 30, 2024 and the fiscal year ended December 31, 2024.

(1) Explanation of operating results

The Group's Mission is to use the diverse capabilities of its people and core technologies as an engine for growth to create highly competitive, feature-rich products and services that realize customer value and contribute to better lives for all.

Guided by this Mission, we established our Sustainability Vision as our long-term vision for 2030, and aim to create economic and social value by contributing to solving global social issues in the priority markets of Medical, Mobility, and Sustainable Materials, with the integration and orchestration of the diverse talents of our people and our technologies. Correspondingly, we have formulated and implemented the 8th Medium-term Business Plan that sets forth the medium-term plan to be achieved in the three years from fiscal 2024 to 2026 and a strategy to get there, reflecting backwards the Sustainability Vision. Aiming to achieve stable growth and increased capital efficiency, we will improve and stabilize profitability by strengthening the business portfolio we have built up to date.

During the six months ended June 30, 2025, the global economy continued to trend toward recovery, though uncertainty over the future heightened due to developments relating to the U.S. tariff policies and geopolitical risks. In the United States, the economy slightly slowed but remained firm due to widespread uncertainty concerning tariff policies. In Europe, the economy trended toward recovery against the backdrop of a rush demand before the imposition of the additional U.S. tariffs and an increase in consumer spending. In China, although the economy showed a moderate recovery driven by government economic stimulus measures, foreign demand remained sluggish, and the overall economic recovery lacked momentum. Meanwhile, the Japanese economy showed signs of a moderate recovery, constrained by sluggish external demand and other factors.

Under these conditions, during the six months ended June 30, 2025, product demand remained steady in the Industrial Materials and the Medical Technologies segments, and the company acquired in the pharmaceutical business during the current period began to contribute to earnings. In the Devices segment, product demand for tablets exceeded expectations due to a surge in purchase ahead of the implementation of the additional U.S. tariffs. However, it declined compared to the same period of the previous year, when demand was firm by new product launches. In addition to these, foreign exchange loss was recorded under other expenses.

As a result, regarding the financial results for the six months ended June 30, 2025, net sales were ¥97,049 million (a decrease of 2.6% as compared to the same period of the previous year), operating profit was ¥2,693 million (a decrease of 36.9% as compared to the same period of the previous year) and profit attributable to owners of parent was ¥129 million (a decrease of 97.0% as compared to the same period of the previous year).

Following is an overview by business segment.

Industrial Materials

In the Industrial Materials segment, we mainly offer proprietary technologies that enable to create added value on the surfaces of various materials. IMD, IML, and IME, which facilitate simultaneous in-mold decoration, design and function adding of plastic products, are extensively used in mobility components and home appliances in global markets. Also, the metallized paper, which unites the properties of metallic luster and printing friendliness, has the largest market share in the

industry as sustainable materials for beverages and foods on a global basis.

During the six months ended June 30, 2025, demand for mobility components in the field of decorations remained firm, and that for home appliances and items such as the metallized paper in the field of sustainable materials was steady. These demand trends helped to increase net sales year on year, while operating profit decreased year on year mainly due to upfront costs associated with new products for mobility components.

As a result, segment sales for the six months ended June 30, 2025 were ¥37,570 million (an increase of 0.9% as compared to the same period of the previous year). Segment profit (operating profit) was 2,169 million (a decrease of 19.6% as compared to the same period of the previous year).

Devices

In the Devices segment, we produce components and module products that pursue precision and functionality. Our main products, film-based Touch Sensors are widely adopted mainly in tablets, handheld terminals (logistics related), mobility components, and gaming devices in global markets. In addition, we offer gas sensors that can detect gas conditions, along with other products.

During the six months ended June 30, 2025, although the demand for tablets exceeded expectations due to a surge in purchase ahead of the implementation of additional U.S. tariffs, it declined compared to the same period of the previous year, when demand was firm by new product launches. Accordingly, net sales and operating profit decreased year on year, despite improvements in efficiency and productivity following the revision of the production structure.

As a result, segment sales for the six months ended June 30, 2025 were ¥29,752 million (a decrease of 18.0% as compared to the same period of the previous year). Segment profit (operating profit) was ¥ 1,097 million (a decrease of 41.4% as compared to the same period of the previous year).

Medical Technologies

The Medical Technologies segment is a business segment that offers high-quality and value-added products in medical devices and other related markets to contribute to healthy and affluent life. The segment currently provides contract design/development and manufacturing services for major medical device manufacturers, especially for those in North America and Europe, with products such as surgical instruments for minimal invasive medical treatments and medical wearable sensors used for a wide range of therapeutic areas. In addition to these, the segment manufactures and sells its own brand products to medical institutions.

During the six months ended June 30, 2025, both net sales and operating profit increased year on year, driven by steady demand for our mainstay contract design/development manufacturing services for medical devices and the contribution to earnings from companies acquired on March 1, 2024, among other factors.

As a result, segment sales for the six months ended June 30, 2025 were ¥23,459 million (an increase of 6.5% as compared to the same period of the previous year). Segment profit (operating profit) was ¥1,267 million (an increase of 23.2% as compared to the same period of the previous year).

(2) Explanation of financial position

1) Assets, liabilities and equity

Total assets as of June 30, 2025 decreased by ¥12,290 million from the end of the previous year (the fiscal year ended December 31, 2024) to ¥239,655 million.

Current assets decreased by ¥15,767 million from the end of the previous year to ¥112,859 million. This was mainly because of a ¥13,122 million decrease of cash and cash equivalents, a ¥685 million decrease of trade and other receivables and a ¥2,609 million decrease of inventories.

Non-current assets increased by ¥3,476 million from the end of the previous year to ¥126,796 million. This was mainly because of a ¥1,317 million increase of property, plant and equipment, a ¥1,042 million increase of goodwill due to new acquisition and others, an ¥816 million increase of right-of-use assets and a ¥717 million increase of other financial assets mainly due to a change in fair value of financial assets measured at fair value through other comprehensive income.

Total liabilities as of June 30, 2025 decreased by ¥8,134 million from the end of the previous year to ¥128,599 million.

Current liabilities increased by ¥3,479 million from the end of the previous year to ¥67,461 million. This was mainly due to a ¥10,031 million increase of bonds and borrowings resulting from transfers from non-current liabilities outweighed a ¥1,385 million decrease of trade and other payables, a ¥1,748 million decrease of other financial liabilities, and a ¥1,906 million decrease of income taxes payable, etc.

Non-current liabilities decreased by ¥11,613 million from the end of the previous year to ¥61,138 million. This was mainly because of a ¥11,959 million decrease of bonds and borrowings mainly due to transfers to current liabilities.

Total equity as of June 30, 2025 decreased by ¥4,156 million from the end of the previous year to ¥111,055 million. This was mainly because of a ¥1,060 million decrease of retained earnings due to dividends of surplus and a ¥4,272 million decrease of other components of equity due to the impact of foreign exchange conversion, etc., outweighed a ¥738 million increase of capital surplus due to changes in non-controlling interests.

2) Cash flows

The balance of cash and cash equivalents (the “funds”) on a consolidated basis as of June 30, 2025 was ¥37,847 million, a decrease of ¥13,122 million compared to the end of the previous year.

The following describes the conditions of each cash flow and the underlying causes for the six months ended June 30, 2025.

(Net cash provided by (used in) operating activities)

The funds provided by operating activities amounted to ¥3,075 million (a decrease of 71.7% as compared to the same period of the previous year). This was mainly because there were ¥1,218 million in profit before tax, ¥4,835 million in depreciation and amortization, a ¥1,066 million decrease in trade and other receivables and a ¥2,228 million decrease in inventories, while there were a ¥2,090 million decrease in trade and other payables and a ¥2,771 million in income taxes paid.

(Net cash provided by (used in) investing activities)

The funds used in investing activities amounted to ¥9,831 million (a decrease of 25.9% as compared to the same period of the previous year). This was mainly because of ¥3,191 million of purchase of property, plant and equipment, ¥750 million of purchase of intangible assets and ¥5,001 million of payments for acquisition of subsidiaries.

(Net cash provided by (used in) financing activities)

The funds used in financing activities amounted to ¥3,818 million (¥5,810 million provided for the same period of the previous year). This was mainly because there was ¥1,518 million in proceeds from short-term borrowings, while there

were ¥1,088 million in repayments of short-term borrowings, ¥1,043 million in repayments of lease liabilities, ¥1,314 million in repayments of long-term borrowings, and ¥1,191 million in dividends paid to owners of parent.

(3) Explanation of consolidated operating results forecast and other forecast information

For the consolidated financial forecasts for the fiscal year ending December 31, 2025, as a result of reviewing the operating results and other factors for the six months ended June 30, 2025, the operating results forecast announced on February 13, 2025 has been revised.

For details, please see the “Notice of Difference between Business Forecast and Actual Results for the First Half of FY2025 and Revision to the Business Forecast for FY2025” announced today (on August 6, 2025).

2. Condensed Consolidated Financial Statements and Principal Notes

(1) Condensed consolidated statements of financial position

(Million yen)

	As of December 31, 2024	As of June 30, 2025
Assets		
Current assets		
Cash and cash equivalents	50,970	37,847
Trade and other receivables	37,588	36,903
Inventories	35,730	33,120
Other financial assets	178	263
Other current assets	4,159	4,724
Total current assets	128,627	112,859
Non-current assets		
Property, plant and equipment	46,475	47,792
Goodwill	34,015	35,057
Intangible assets	18,081	17,423
Right-of-use assets	9,408	10,225
Investments accounted for using equity method	5,136	5,175
Other financial assets	9,015	9,733
Retirement benefit asset	80	80
Deferred tax assets	747	957
Other non-current assets	357	350
Total non-current assets	123,319	126,796
Total assets	251,946	239,655

(Million yen)

	As of December 31, 2024	As of June 30, 2025
Liabilities and equity		
Liabilities		
Current liabilities		
Trade and other payables	32,129	30,744
Borrowings	16,958	26,990
Other financial liabilities	2,700	952
Lease liabilities	1,910	2,068
Income taxes payable, etc.	2,638	731
Provisions	56	38
Other current liabilities	7,588	5,936
Total current liabilities	63,982	67,461
Non-current liabilities		
Bonds and borrowings	45,338	33,378
Other financial liabilities	7,123	6,548
Lease liabilities	8,577	9,198
Retirement benefit liability	5,267	5,384
Provisions	60	67
Deferred tax liabilities	5,995	6,086
Other non-current liabilities	388	474
Total non-current liabilities	72,751	61,138
Total liabilities	136,734	128,599
Equity		
Share capital	12,119	12,119
Capital surplus	10,391	11,130
Retained earnings	76,839	75,778
Treasury shares	(5,553)	(6,157)
Other components of equity	20,231	15,958
Total equity attributable to owners of parent	114,028	108,829
Non-controlling interests	1,183	2,226
Total equity	115,212	111,055
Total liabilities and equity	251,946	239,655

(2) Condensed consolidated statements of profit or loss and comprehensive income

Condensed consolidated statements of profit or loss

(Million yen)

	Six Months Ended June 30, 2024	Six Months Ended June 30, 2025
Net sales	99,661	97,049
Cost of sales	(76,949)	(74,459)
Gross profit	22,711	22,589
Selling, general and administrative expenses	(18,281)	(19,176)
Other income	583	233
Other expenses	(594)	(789)
Share of profit (loss) of investments accounted for using equity method	(153)	(164)
Operating profit (loss)	4,266	2,693
Finance income	2,549	296
Finance costs	(808)	(1,771)
Profit (loss) before tax	6,007	1,218
Income tax expense	(1,687)	(856)
Profit (loss)	4,320	361
Profit (loss) attributable to:		
Owners of parent	4,258	129
Non-controlling interests	61	232
Profit (loss)	4,320	361
Earnings (loss) per share attributable to owners of parent		
Basic earnings (loss) per share (Yen)	88.04	2.72
Diluted earnings (loss) per share (Yen)	—	—

Condensed consolidated statements of comprehensive income

(Million yen)

	Six Months Ended June 30, 2024	Six Months Ended June 30, 2025
Profit (loss)	4,320	361
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Net change in fair value of financial assets measured through other comprehensive income	1,813	315
Remeasurements of defined benefit plans	22	-
Total of items that will not be reclassified to profit or loss	1,836	315
Items that may be reclassified to profit or loss		
Exchange differences on translation of foreign operations	8,348	(4,531)
Share of other comprehensive income of investments accounted for using equity method	573	(165)
Total of items that may be reclassified to profit or loss	8,921	(4,696)
Total other comprehensive income	10,758	(4,380)
Total comprehensive income	15,078	(4,018)
Comprehensive income attributable to:		
Owners of parent	14,940	(4,139)
Non-controlling interests	137	121
Total comprehensive income	15,078	(4,018)

(3) Condensed consolidated statements of changes in equity

(Million yen)

	Equity attributable to owners of parent										
	Share capital	Capital surplus	Retained earnings	Treasury shares	Other components of equity				Total equity attributable to owners of parent	Non-controlling interests	Total equity
					Net change in fair value of financial assets measured through other comprehensive income	Remeasurements of defined benefit plans	Exchange differences on translation of foreign operations	Total other components of equity			
Balance at January 1, 2024	12,119	14,865	69,934	(4,019)	7,684	—	10,329	18,013	110,913	(60)	110,852
Profit (loss)	—	—	4,258	—	—	—	—	—	4,258	61	4,320
Other comprehensive income	—	—	—	—	1,813	22	8,846	10,682	10,682	75	10,758
Total comprehensive income	—	—	4,258	—	1,813	22	8,846	10,682	14,940	137	15,078
Purchase of treasury shares	—	—	—	(635)	—	—	—	—	(635)	—	(635)
Disposal of treasury shares	—	(161)	—	320	—	—	—	—	159	—	159
Dividends of surplus	—	—	(1,215)	—	—	—	—	—	(1,215)	—	(1,215)
Share-based payment transactions	—	29	—	—	—	—	—	—	29	—	29
Changes in ownership interest	—	(65)	—	—	—	—	—	—	(65)	61	(3)
Increase (decrease) by business combination	—	—	—	—	—	—	—	—	—	1,004	1,004
Put options granted to non-controlling interests	—	(3,512)	—	—	—	—	—	—	(3,512)	—	(3,512)
Transfer from other components of equity to retained earnings	—	—	22	—	—	(22)	—	(22)	—	—	—
Total transactions with owners, etc.	—	(3,709)	(1,192)	(314)	—	(22)	—	(22)	(5,240)	1,066	(4,173)
Balance at June 30, 2024	12,119	11,155	73,000	(4,334)	9,498	—	19,175	28,673	120,614	1,143	121,757
Balance at January 1, 2025	12,119	10,391	76,839	(5,553)	3,067	—	17,163	20,231	114,028	1,183	115,212
Profit (loss)	—	—	129	—	—	—	—	—	129	232	361
Other comprehensive income	—	—	—	—	315	—	(4,584)	(4,269)	(4,269)	(111)	(4,380)
Total comprehensive income	—	—	129	—	315	—	(4,584)	(4,269)	(4,139)	121	(4,018)
Purchase of treasury shares	—	—	—	(655)	—	—	—	—	(655)	—	(655)
Disposal of treasury shares	—	(14)	—	51	—	—	—	—	36	—	36
Dividends of surplus	—	—	(1,193)	—	—	—	—	—	(1,193)	(81)	(1,274)
Share-based payment transactions	—	31	—	—	—	—	—	—	31	—	31
Changes in ownership interest	—	721	—	—	—	—	—	—	721	250	972
Increase (decrease) by business combination	—	—	—	—	—	—	—	—	—	752	752
Put options granted to non-controlling interests	—	—	—	—	—	—	—	—	—	—	—
Transfer from other components of equity to retained earnings	—	—	3	—	(3)	—	—	(3)	—	—	—
Total transactions with owners, etc.	—	738	(1,189)	(603)	(3)	—	—	(3)	(1,059)	921	(137)
Balance at June 30, 2025	12,119	11,130	75,778	(6,157)	3,380	—	12,578	15,958	108,829	2,226	111,055

(4) Condensed consolidated statements of cash flows

(Million yen)

	Six Months Ended June 30, 2024	Six Months Ended June 30, 2025
Cash flows from operating activities		
Profit (loss) before tax	6,007	1,218
Depreciation and amortization	4,803	4,835
Loss (gain) on sale and retirement of fixed assets	4	(21)
Share of loss (profit) of investments accounted for using equity method	153	164
Finance income	(2,549)	(296)
Finance costs	808	1,771
Decrease (increase) in trade and other receivables	(5,145)	1,066
Decrease (increase) in inventories	(1,247)	2,228
Increase (decrease) in trade and other payables	8,157	(2,090)
Increase (decrease) in provisions	40	(34)
Increase (decrease) in retirement benefit asset or liability	(578)	(1,248)
Other	403	(1,243)
Subtotal	10,856	6,350
Interest received	216	201
Dividends received	222	96
Interest paid	(735)	(829)
Income taxes paid	(716)	(2,771)
Income taxes refund	1,034	28
Net cash provided by (used in) operating activities	10,879	3,075
Cash flows from investing activities		
Purchase of property, plant and equipment	(2,866)	(3,191)
Payments for retirement of property, plant and equipment	(0)	(22)
Proceeds from sale of property, plant and equipment	18	97
Purchase of intangible assets	(1,024)	(750)
Purchase of investment securities	(138)	(318)
Proceeds from sale of investment securities	—	51
Payments for acquisition of subsidiaries	(9,166)	(5,001)
Purchase of shares of affiliates	(540)	(291)
Other	457	(405)
Net cash provided by (used in) investing activities	(13,260)	(9,831)

(Million yen)

	Six Months Ended June 30, 2024	Six Months Ended June 30, 2025
Cash flows from financing activities		
Proceeds from short-term borrowings	9,585	1,518
Repayments of short-term borrowings	(353)	(1,088)
Repayments of lease liabilities	(1,070)	(1,043)
Proceeds from long-term borrowings	857	–
Repayments of long-term borrowings	(1,290)	(1,314)
Purchase of treasury shares	(635)	(655)
Proceeds from sale of treasury shares	149	37
Decrease (increase) in deposit paid for repurchase of treasury stock	639	–
Dividends paid to owners of parent	(1,213)	(1,191)
Dividends paid to non-controlling interests	–	(81)
Other	(857)	–
Net cash provided by (used in) financing activities	5,810	(3,818)
Effect of exchange rate changes on cash and cash equivalents	3,633	(2,548)
Net increase (decrease) in cash and cash equivalents	7,063	(13,122)
Cash and cash equivalents at beginning of period	37,854	50,970
Cash and cash equivalents at end of period	44,917	37,847

(5) Notes to condensed consolidated financial statements

(Notes to going concern assumptions)

Not applicable

(Segment information)

1. Description of reportable segments

The Group's reportable segments are those for which separate financial information is available and regular evaluation by the board of directors is being performed in order to decide the allocation of management resources and to review business results.

The Group sets up divisions by product or service. Each division draws up a plan for comprehensive strategies in Japan and overseas for the products and services it handles, and thereupon develops its business activities.

Accordingly, the Group consists of segments by product and service based on divisions. The three reportable segments are the Industrial Materials segment, the Devices segment, and the Medical Technologies segment.

The Industrial Materials segment manufactures and sells decorative films, decorative molded parts, metallized papers, sustainable molded products, and others. The Devices segment manufactures and sells film-based Touch Sensors, gas sensors, and others. The Medical Technologies segment provides contract design/development and manufacturing services for major medical device manufacturers, especially for those in North America and Europe, along with products such as surgical instruments for minimally invasive treatments, medical wearable sensors, and disposable electrocardiogram (ECG) electrodes. In addition to these, the segment manufactures and sells its own brand products to medical institutions.

2. Methods of measurement for the amounts of sales and profit (loss) for each reportable segment

The accounting methods for the reportable segments are the same as those used in preparing the consolidated financial statements. Segment profit is based on operating profit, and inter-segment sales are based on current market prices.

3. Information about sales and profit (loss) by reportable segment

Six months ended June 30, 2024 (January 1, 2024 to June 30, 2024)

	Reportable segment				Other (Note 1)	Total	Reconcili- ations (Note 2)	Consolidated (Note 3)
	Industrial Materials	Devices	Medical Technologies	Sub-total				
Sales from external customers	37,220	36,273	22,024	95,518	4,142	99,661	—	99,661
Inter-segment sales	30	0	—	30	486	517	(517)	—
Total	37,250	36,274	22,024	95,549	4,629	100,179	(517)	99,661
Segment profit (loss)	2,699	1,873	1,028	5,601	(420)	5,181	(915)	4,266
Finance income	—	—	—	—	—	—	—	2,549
Finance costs	—	—	—	—	—	—	—	(808)
Profit (loss) before tax	—	—	—	—	—	—	—	6,007

(Notes) 1. The “Other” category consists of a business segment not included in the reportable segments and includes the Information and Communication, the prescription pharmaceutical manufacturing business, etc.

2. The negative ¥915 million of reconciliations in segment profit (loss) includes unallocated corporate expenses, etc. Corporate expenses mainly consist of general and administrative expenses and foreign exchange loss or gain not attributable to any reportable segment.

3. Segment profit (loss) is reconciled with operating profit (loss) recorded in the condensed consolidated statements of profit or loss.

4. In the six months ended June 30, 2025, the Company finalized the provisional accounting treatment for business combination. Accordingly, the figures for the six months ended June 30, 2024 have been retroactively adjusted to reflect the finalization of the provisional accounting treatment.

Six months ended June 30, 2025 (January 1, 2025 to June 30, 2025)

	Reportable segment				Other (Note 1)	Total	Reconcili- ations (Note 2)	Consolidated (Note 3)
	Industrial Materials	Devices	Medical Technologies	Sub-total				
Sales from external customers	37,570	29,752	23,459	90,781	6,267	97,049	—	97,049
Inter-segment sales	52	9	—	61	495	556	(556)	—
Total	37,622	29,761	23,459	90,843	6,762	97,605	(556)	97,049
Segment profit (loss)	2,169	1,097	1,267	4,534	365	4,899	(2,205)	2,693
Finance income	—	—	—	—	—	—	—	296
Finance costs	—	—	—	—	—	—	—	(1,771)
Profit (loss) before tax	—	—	—	—	—	—	—	1218

(Notes) 1. The “Other” category consists of a business segment not included in the reportable segments and includes the Information and Communication, the prescription pharmaceutical manufacturing business, etc.

2. The negative ¥2,205 million of reconciliations in segment profit (loss) includes unallocated corporate expenses, etc. Corporate expenses mainly consist of general and administrative expenses and foreign exchange loss or gain not attributable to any reportable segment.

3. Segment profit (loss) is reconciled with operating profit (loss) recorded in the condensed consolidated statements of profit or loss.